NASDAQ:CYTK
Cytokinetics Stock News
$65.34
+0.540 (+0.83%)
At Close: Apr 26, 2024
Analysts Expect Cytokinetics, Inc. (NASDAQ:CYTK) Will Announce Earnings of -$0.50 Per Share
09:58am, Saturday, 18'th Apr 2020
Analysts forecast that Cytokinetics, Inc. (NASDAQ:CYTK) will report ($0.50) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Cytokinetics’ earn
The Cytokinetics (NASDAQ:CYTK) Share Price Is Up 93% And Shareholders Are Holding On
05:02pm, Friday, 17'th Apr 2020
Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...
10 Biggest Price Target Changes For Friday
12:14pm, Friday, 17'th Apr 2020
Goldman Sachs cut Apple Inc. (NASDAQ: AAPL) price target from $250 to $233. Apple shares closed at $286.69 on Thursday.
Raymond James lowered the price target on Union Pacific...
Cytokinetics price target raised to $23 from $12 at Cantor Fitzgerald CYTK
11:39am, Friday, 17'th Apr 2020
Cytokinetics price target raised to $23 from $12 at Cantor Fitzgerald Cantor Fitzgerald CYTK
$4.92 Million in Sales Expected for Cytokinetics, Inc. (NASDAQ:CYTK) This Quarter
05:16am, Friday, 17'th Apr 2020
Brokerages expect Cytokinetics, Inc. (NASDAQ:CYTK) to report sales of $4.92 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cytokinetics’ e
Cantor Fitzgerald Reiterates Overweight on Cytokinetics, Raises Price Target to $23
12:00am, Friday, 17'th Apr 2020Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by Needham & Company LLC
07:34am, Thursday, 16'th Apr 2020
Cytokinetics (NASDAQ:CYTK)‘s stock had its “buy” rating restated by Needham & Company LLC in a research note issued on Tuesday, AnalystRatings.com reports. They currently have a $24.00 target pr
Morgan Stanley Sticks to Its Hold Rating for Voyager Therapeutics (VYGR)
03:43pm, Wednesday, 15'th Apr 2020
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Voyager Therapeutics (VYGR), with a price target of $13.00. The
Cytokinetics (NASDAQ:CYTK) Rating Reiterated by HC Wainwright
07:34am, Wednesday, 15'th Apr 2020
Cytokinetics (NASDAQ:CYTK)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Tuesday, TipRanks reports. They presently have a $30.0
Cytokinetics (CYTK) Received its Third Buy in a Row
03:16pm, Tuesday, 14'th Apr 2020
After Morgan Stanley and Needham gave Cytokinetics (NASDAQ: CYTK) a Buy rating last month, the company received another Buy, this time from H.C.
Cytokinetics (CYTK) Received its Third Buy in a Row
03:15pm, Tuesday, 14'th Apr 2020
After Morgan Stanley and Needham gave Cytokinetics (NASDAQ: CYTK) a Buy rating last month, the company received another Buy, this
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Cytokinetics (CYTK), with a price target of $24.00. The company's shares
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today,
Chad Messer
from Needham reiterated a
Buy
rating on Cytokinetics (
CYTK
–
Research Report
), with a price target of
$24.00
. The company’s shares closed last Tuesday at
Cytokinetics suspends enrollment in clinical studies amid COVID-19; shares down 7% premarket
12:17pm, Tuesday, 14'th Apr 2020
Cytokinetics (NASDAQ:CYTK) provides clinical updates in response to COVID-19 pandemic. The company and Amgen have agreed to temporarily suspend enrollment in METEORIC-HF, Phase 1 study of AMG 594 an
Cytokinetics says cash, cash equivalents represent over two years of runway CYTK
11:47am, Tuesday, 14'th Apr 2020
Cytokinetics says cash, cash equivalents represent over two years of runway CYTK
